Synapse Drugs Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 10 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth %
- Ebitda
- Net Worth
- Total Assets 11.61%
About Synapse Drugs
Synapse Drugs Private Limited (SDPL) is a Private Limited Indian Non-Government Company incorporated in India on 03 December 2014 and has a history of Ten years and two months. Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Infrastructure And Utilities Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Niranjanrao Errabelli, Venkata Vala, and Sucharitha Vala serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24232TG2014PTC096661
- Company No.
096661
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Dec 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Synapse Drugs?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Niranjanrao Errabelli  | Director | 03-Dec-2014 | Current |
| Venkata Vala | Director | 03-Dec-2014 | Current |
| Sucharitha Vala | Additional Director | 01-May-2019 | Current |
Financial Performance of Synapse Drugs.
Synapse Drugs Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Synapse Drugs?
In 2019, Synapse Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Yamini Films Private LimitedSucharitha Vala is a mutual person
Uma Kanmanthreddy Estates LlpVenkata Vala and Sucharitha Vala are mutual person
- Bvslh Estates Llp
Venkata Vala is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Synapse Drugs?
Unlock and access historical data on people associated with Synapse Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Synapse Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Synapse Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.